The post title is a copy and paste from the title, subtitle and second paragraph of the linked popular press article here:
Scientists Discover Two New Cannabinoids
THCP and CBDP demonstrate how much more we have to learn from studying marijuana.
The first, tetrahydrocannabiphorol (THCP), is allegedly 30 times more potent than THC, they claim. Whether that means it gets you 30 times as stoned—or if it’s even psychoactive at all—is still unknown. But in mice, it appeared THCP was more active than THC at lower doses. The scientists also found cannabidiphorol (CBDP), a cousin to CBD, the popular wellness additive.
Journal Reference:
Citti, C., Linciano, P., Russo, F. et al.
A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol.
Sci Rep 9, 20335 (2019)
Link: https://www.nature.com/articles/s41598-019-56785-1
doi:10.1038/s41598-019-56785-1
Abstract
(-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC itself. In the attempt to define the phytocannabinoids profile that characterizes a medicinal cannabis variety, a new phytocannabinoid with the same structure of Δ9-THC but with a seven-term alkyl side chain was identified. The natural compound was isolated and fully characterized and its stereochemical configuration was assigned by match with the same compound obtained by a stereoselective synthesis. This new phytocannabinoid has been called (-)-trans-Δ9-tetrahydrocannabiphorol (Δ9-THCP). Along with Δ9-THCP, the corresponding cannabidiol (CBD) homolog with seven-term side alkyl chain (CBDP) was also isolated and unambiguously identified by match with its synthetic counterpart. The binding activity of Δ9-THCP against human CB1 receptor in vitro (Ki = 1.2 nM) resulted similar to that of CP55940 (Ki = 0.9 nM), a potent full CB1 agonist. In the cannabinoid tetrad pharmacological test, Δ9-THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity. The presence of this new phytocannabinoid could account for the pharmacological properties of some cannabis varieties difficult to explain by the presence of the sole Δ9-THC.